MIRM
Mirum Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$96.97
+11.42%Next report
Analyst consensus
- Next report date
- Feb 24, 2027
- EPS estimate
- -$0.58
- Revenue estimate
- $194.5M
Latest reported
- Last report date
- Nov 3, 2026
- EPS actual
- -$0.87
- EPS estimate
- -$0.49
- Revenue actual
- $185.7M
- Revenue estimate
- $178.1M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -1007.2%
- Revenue beats (12Q)
- 9
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $160
- PT range
- $130 – $202
- Analysts
- 10
10 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 3, 2026 | -$0.49 | -$0.87 | Miss -78.71% | $185.7M |
| Aug 5, 2026 | -$0.74 | -$1.06 | Miss -42.75% | $176.2M |
| May 6, 2026 | -$0.40 | -$13 | Miss -3257.50% | $159.9M |
| Feb 25, 2026 | $0.02 | -$0.11 | Miss -650.00% | $148.9M |
| Aug 6, 2025 | -$0.31 | -$0.12 | Beat 61.29% | $127.8M |
| Feb 26, 2025 | -$0.27 | -$0.49 | Miss -81.48% | $99.4M |
| Feb 28, 2024 | -$0.34 | -$0.66 | Miss -94.12% | $69.6M |
| Nov 2, 2023 | -$0.64 | -$0.57 | Beat 10.94% | $47.7M |
| Aug 3, 2023 | -$0.81 | -$0.92 | Miss -13.58% | $37.5M |
| May 4, 2023 | -$0.96 | -$0.80 | Beat 16.67% | $31.6M |
| Mar 8, 2023 | -$0.98 | -$0.99 | Miss -1.02% | $27.9M |
| Aug 4, 2022 | -$1.05 | -$0.84 | Beat 20.00% | $17.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 24, 2027